IOLCP Showing Change in Structure can go towards 52 Week High
IOLCP ......................................................................................................................
......................................................................................................................
The Company’s turnover
increased to ₹ 2,133 crore in
FY24 from ₹ 983 crore in FY18
at a CAGR of 13.77%
......................................................................................................................
......................................................................................................................
The share of regulated
market sale has increased
to ₹ 300 crore in FY24 from
₹100 crore in FY18
......................................................................................................................
......................................................................................................................
Increased contribution
of non-Ibuprofen drugs
from ₹35 crore in FY18
to ₹431 crore in FY24,
showing a steady upward
trend over the years
......................................................................................................................
......................................................................................................................
Added more than 10
products since 2017 in
APIs and chemical segments.
The Company has
recently commenced a new
plant of Acetic Anhydride
......................................................................................................................
......................................................................................................................
• The Indian API market is expected to grow at a
CAGR of 13.7% over the four years.
• India hosts 500 API manufacturers, contributing
approximately 8% to the global API Industry.
• As the largest supplier of generic medicines,
India manufactures around 60,000 different
generic brands across 60 therapeutic categories.
• In FY24 India saw a 4.12% increase in the total
imports of bulk drugs and intermediates,
amounting to ₹ 37,721.88 crore, compared to ₹
36,229.15 crore in FY23.
• Indian medicines are preferred worldwide due to
their combination of low price and high quality,
earning India the title of "pharmacy of the
world."
......................................................................................................................
......................................................................................................................
Positive factors
• Strongly improving operating performance, resulting in growth of more than 15% in total operating income and sustained
EBIDTA margin of more than 20%, on a sustained.
• Diversifying product portfolio and reducing dependency on its main product Ibuprofen and ethyl acetate to below 65% in the
overall revenue.
• Improving total debt to gross cash accruals (TD/GCA) and TD to profit before interest, lease rentals, depreciation, and taxation
(TD/PBILDT) to below unity.
......................................................................................................................
......................................................................................................................
Established market position and diversified product offering
The company was incorporated, 1986 with the commencement of business in chemical segment.
In 2000, the company started
production of Ibuprofen.
IOLCPL is one of the largest manufacturers of Ibuprofen with significant global share and the company
is backward integrated for manufacturing Ibuprofen.
IOLCPL has a market presence across more than 50 countries with sales
contribution from exports forming around 28% of total sales in FY24 (PY: 29%).
The company’s overseas customers are spread
across Switzerland, Bangladesh, Spain, Indonesia, Hungary, United Kingdom, Nepal, China, Turkey and Japan, among others.
The company is one of the largest manufacturers of Ibuprofen (capacity of 12000 MTPA) and has the second largest manufacturing
capacity (12000MTPA) for Iso Butyl Benzene (key raw material for Ibuprofen)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.